The Brown University Child and Adolescent Psychopharmacology Update articles from October 2009

The Brown University Child and Adolescent Psychopharmacology Update archives from October 2009

AACAP issues practice parameter on psychotropic use in pediatrics.(Practice Guide)
October 1, 2009... A document from the American Academy of Child and Adolescent Psychiatry (AACAP) on the use of psychotropic medications in children and adolescents is now available for clinicians. Its stated aim is to promote "the appropriate and safe use of...

Review finds several medications effective and safe for ADHD with comorbid tics.(Comorbidity)
October 1, 2009... A meta-analysis of randomized, placebo-controlled trials involving children with attention-deficit/hyperactivity disorder (ADHD) and comorbid tic disorders has found that four of six medications studied have demonstrated efficacy in treating...

Reboxetine in ADHD children with MPH intolerance.(What's New In Research)
October 1, 2009... Reboxetine may offer an alternative treatment for children with attention-deficit/hyperactivity disorder (ADHD) who cannot tolerate methylphenidate (MPH). According to preliminary results from an 8-week, open-label study, reboxetine resulted in...

Training, stimulants improve WM in ADHD children.
October 1, 2009... Specific cognitive deficits can potentially be overcome in children with attention-deficit/hyperactivity disorder (ADHD) using either psychostimulants or the Cogmed Working Memory Training program, according to a recent study. Stimulant...

AM versus PM dosing of atomoxetine for ADHD.(News Notes)
October 1, 2009... Once-daily atomoxetine taken in the morning or evening significantly reduced core symptoms of attention-deficit/ hyperactivity disorder (ADHD) compared with placebo in 6-to 12-year-old children, according to a new trial. However, morning dosing...

Increased teen abuse of ADHD drugs.(News Notes)
October 1, 2009... Abuse of drugs used for treating attention-deficit/hyperactivity disorder (ADHD) has increased significantly over a recent 8-year period among adolescents, according to a new study published ahead of print in Pediatrics. The findings are based...

Perinatal anesthetic exposure and neurodevelopmental outcomes.(News Notes)
October 1, 2009... Children exposed to anesthesia during cesarean delivery are no more likely to develop learning disabilities (LDs) than are children delivered vaginally. A new study conducted by Mayo Clinic researchers investigated medical records of 5,320...

Escitalopram-induced dyskinesia and EPS.(Case Report)
October 1, 2009... Patient: Male, 12 years old Medications: Alprazolam (Xanax), diphenhydramine (Benadryl), escitalopram (Lexapro), rabeprazole (Aciphex) Case: A 12-year-old boy had been treated for 5 days with rabeprazole for retrosternal pain and anxiety....

New approvals.(From the FDA)
October 1, 2009... Paliperidone (Invega) was approved on July 31, 2009 as the first and only antipsychotic for the acute treatment of schizoaffective disorder. Invega is marketed in the U.S. by Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc....

Citalopram HBr (brand: Celexa).(PATIENT INFORMATION SHEET)
October 1, 2009... What is citalopram? Citalopram is in a class of antidepressant medications called selective serotonin reuptake inhibitors (SSRIs). What is citalopram used for? Citalopram has an FDA-approved indication for the treatment of depression in...